{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:24:28Z","timestamp":1794320668474,"version":"4.9.0"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"2","funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA181385"],"award-info":[{"award-number":["R01CA181385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["U54CA210190"],"award-info":[{"award-number":["U54CA210190"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society (ACS)","doi-asserted-by":"publisher","award":["RSG-14-171-01-CSM"],"award-info":[{"award-number":["RSG-14-171-01-CSM"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["P50CA101955"],"award-info":[{"award-number":["P50CA101955"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000138","name":"U.S. Department of Education (DoED)","doi-asserted-by":"publisher","award":["P200A120198"],"award-info":[{"award-number":["P200A120198"]}],"id":[{"id":"10.13039\/100000138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDA) remains one of the deadliest forms of cancer, in part, because it is largely refractory to current therapies. The failure of most standard therapies in PDA, as well as promising immune therapies, may be largely ascribed to highly unique and protective stromal microenvironments that present significant biophysical barriers to effective drug delivery, that are immunosuppressive, and that can limit the distribution and function of antitumor immune cells. Here, we utilized stromal reengineering to disrupt these barriers and move the stroma toward normalization using a potent antifibrotic agent, halofuginone. In an autochthonous genetically engineered mouse model of PDA, halofuginone disrupted physical barriers to effective drug distribution by decreasing fibroblast activation and reducing key extracellular matrix elements that drive stromal resistance. Concomitantly, halofuginone treatment altered the immune landscape in PDA, with greater immune infiltrate into regions of low hylauronan, which resulted in increased number and distribution of both classically activated inflammatory macrophages and cytotoxic T cells. In concert with a direct effect on carcinoma cells, this led to widespread intratumoral necrosis and reduced tumor volume. These data point to the multifunctional and critical role of the stroma in tumor protection and survival and demonstrate how compromising tumor integrity to move toward a more normal physiologic state through stroma-targeting therapy will likely be an instrumental component in treating PDA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This work demonstrates how focused stromal re-engineering approaches to move toward normalization of the stroma disrupt physical barriers to effective drug delivery and promote antitumor immunity.<\/jats:p>\n                    <jats:p>See related commentary by Huang and Brekken, p. 328<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-18-1334","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T11:27:03Z","timestamp":1541503623000},"page":"372-386","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1158","volume":"79","author":[{"given":"Kianna Y.","family":"Elahi-Gedwillo","sequence":"first","affiliation":[{"name":"1Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota."},{"name":"2University of Minnesota Physical Sciences in Oncology Center, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Carlson","sequence":"additional","affiliation":[{"name":"1Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Zettervall","sequence":"additional","affiliation":[{"name":"1Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo P.","family":"Provenzano","sequence":"additional","affiliation":[{"name":"1Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota."},{"name":"2University of Minnesota Physical Sciences in Oncology Center, Minneapolis, Minnesota."},{"name":"3Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota."},{"name":"4Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota."},{"name":"5Institute for Engineering in Medicine, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"2022061706293043200_bib1","volume-title":"Cancer facts and figures","author":"American Cancer Society","year":"2018"},{"key":"2022061706293043200_bib2","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"2022061706293043200_bib3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"2022061706293043200_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"2022061706293043200_bib6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-16-0322","article-title":"T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma","volume":"5","author":"Stromnes","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2022061706293043200_bib7","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bpj.2016.03.040","article-title":"Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase","volume":"110","author":"DuFort","year":"2016","journal-title":"Biophys J"},{"key":"2022061706293043200_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2012.569","article-title":"Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer","volume":"108","author":"Provenzano","year":"2013","journal-title":"Br J Cancer"},{"key":"2022061706293043200_bib9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"2022061706293043200_bib10","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"PNAS"},{"key":"2022061706293043200_bib11","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1158\/0008-5472.CAN-08-1132","article-title":"Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance","volume":"68","author":"Vonlaufen","year":"2008","journal-title":"Cancer Res"},{"key":"2022061706293043200_bib12","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061706293043200_bib13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","article-title":"Cancer-associated stromal fibroblasts promote pancreatic tumor progression","volume":"68","author":"Hwang","year":"2008","journal-title":"Cancer Res"},{"key":"2022061706293043200_bib14","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2353\/ajpath.2010.090899","article-title":"Role of pancreatic stellate cells in pancreatic cancer metastasis","volume":"177","author":"Xu","year":"2010","journal-title":"Am J Pathol"},{"key":"2022061706293043200_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Ohlund","year":"2017","journal-title":"J Exp Med"},{"key":"2022061706293043200_bib16","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"PNAS"},{"key":"2022061706293043200_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2017.06.022","article-title":"Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy","volume":"261","author":"Mpekris","year":"2017","journal-title":"J Control Rel"},{"key":"2022061706293043200_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biomaterials.2018.01.014","article-title":"Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy","volume":"159","author":"Zhao","year":"2018","journal-title":"Biomaterials"},{"key":"2022061706293043200_bib20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","article-title":"A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma","volume":"45","author":"Ko","year":"2016","journal-title":"Pancreas"},{"key":"2022061706293043200_bib21","first-page":"479","article-title":"Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts","volume":"18","author":"Nelson","year":"2012","journal-title":"Mol Vis"},{"key":"2022061706293043200_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"Keller","year":"2012","journal-title":"Nat Chem Biol"},{"key":"2022061706293043200_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/MPA.0b013e3181da8aa3","article-title":"Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development","volume":"39","author":"Spector","year":"2010","journal-title":"Pancreas"},{"key":"2022061706293043200_bib24","doi-asserted-by":"crossref","first-page":"e41833","DOI":"10.1371\/journal.pone.0041833","article-title":"Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice","volume":"7","author":"Spector","year":"2012","journal-title":"PLoS One"},{"key":"2022061706293043200_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MPA.0b013e3181967670","article-title":"Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention","volume":"38","author":"Zion","year":"2009","journal-title":"Pancreas"},{"key":"2022061706293043200_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/jhep.2001.21408","article-title":"Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats","volume":"33","author":"Bruck","year":"2001","journal-title":"Hepatology"},{"key":"2022061706293043200_bib27","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.ejca.2005.12.027","article-title":"Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours","volume":"42","author":"de Jonge","year":"2006","journal-title":"Eur J Cancer"},{"key":"2022061706293043200_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jss.2011.04.021","article-title":"Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method","volume":"172","author":"Ruckert","year":"2012","journal-title":"J Surg Res"},{"key":"2022061706293043200_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib30","doi-asserted-by":"crossref","first-page":"14923","DOI":"10.1038\/ncomms14923","article-title":"Anisotropic forces from spatially constrained focal adhesions mediate contact guidance directed cell migration","volume":"8","author":"Ray","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706293043200_bib31","first-page":"1","article-title":"Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors","volume":"22","author":"Carlson","year":"2017","journal-title":"J Biomed Opt"},{"key":"2022061706293043200_bib32","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2022061706293043200_bib33","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","article-title":"Stromal biology and therapy in pancreatic cancer: a changing paradigm","volume":"64","author":"Neesse","year":"2015","journal-title":"Gut"},{"key":"2022061706293043200_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib35","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/0008-5472.CAN-15-1293","article-title":"TGFbeta signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis","volume":"76","author":"Principe","year":"2016","journal-title":"Cancer Res"},{"key":"2022061706293043200_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1067\/msy.2002.119192","article-title":"Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas","volume":"131","author":"Yen","year":"2002","journal-title":"Surgery"},{"key":"2022061706293043200_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ijc.2910620409","article-title":"Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer","volume":"62","author":"Gress","year":"1995","journal-title":"Int J Cancer"},{"key":"2022061706293043200_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1159\/000007567","article-title":"Role of extracellular matrix in pancreatic diseases","volume":"59","author":"Gress","year":"1998","journal-title":"Digestion"},{"key":"2022061706293043200_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706293043200_bib40","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1073\/pnas.1300415110","article-title":"CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer","volume":"110","author":"Neesse","year":"2013","journal-title":"PNAS"},{"key":"2022061706293043200_bib41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ijc.10963","article-title":"Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer","volume":"104","author":"Muerkoster","year":"2003","journal-title":"Int J Cancer"},{"key":"2022061706293043200_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/excr.1998.4261","article-title":"Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy","volume":"245","author":"Ohmori","year":"1998","journal-title":"Exp Cell Res"},{"key":"2022061706293043200_bib43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte\u2013macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib44","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706293043200_bib45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"2022061706293043200_bib46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","article-title":"T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma","volume":"28","author":"Stromnes","year":"2015","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib47","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1158\/1078-0432.CCR-13-2972","article-title":"Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer","volume":"20","author":"Hartmann","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706293043200_bib48","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022061706293043200_bib49","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022061706293043200_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/jco.2014.32.3_suppl.257","article-title":"A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)","volume":"32","author":"Jesus-Acosta","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022061706293043200_bib51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccr.2014.05.026","article-title":"Pancreatic cancer stroma: friend or foe?","author":"Gore","year":"2014","journal-title":"Cancer Cell"},{"key":"2022061706293043200_bib52","doi-asserted-by":"crossref","first-page":"E3091","DOI":"10.1073\/pnas.1411679111","article-title":"Stromal response to Hedgehog signaling restrains pancreatic cancer progression","volume":"111","author":"Lee","year":"2014","journal-title":"PNAS"},{"key":"2022061706293043200_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: randomized phase II Study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022061706293043200_bib54","first-page":"5002","article-title":"Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium","volume":"59","author":"Olumi","year":"1999","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/2\/372\/2783744\/372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/2\/372\/2783744\/372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:58:26Z","timestamp":1655477906000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/79\/2\/372\/638297\/Antifibrotic-Therapy-Disrupts-Stromal-Barriers-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,15]]},"published-print":{"date-parts":[[2019,1,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-1334","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22421349","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510903.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510903","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22421349.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]}}}